“…In the subgroup analysis of patient source, the meta‐analysis results indicated no significant association between hypertension and PU in Asia group (OR = 1.12, 95% CI = 0.83–1.50, I 2 = 63%, p = 0.46) 11 , 12 , 17 , 20 , 22 , 24 , 25 , 27 , 28 , 29 , 30 , 31 , 32 and Non‐Asia group (OR = 1.20, 95% CI = 0.75–1.94, I 2 = 88%, p = 0.45). 10 , 18 , 19 , 21 , 23 , 26 In the subgroup analysis of study design, the results also showed no significant association between hypertension and PU in cohort study (OR = 1.16, 95% CI = 0.84–1.61, I 2 = 63%, p = 0.36) 10 , 11 , 17 , 21 , 22 , 27 , 28 , 31 , 32 and case–control study (OR = 1.14, 95% CI = 0.79–1.64, I 2 = 82%, p = 0.49). 12 , 18 , 19 , 20 , 23 , 24 , 25 , 26 , 29 , 30 Due to the primary disease difference, subgroup analysis was performed based on primary disease, and the results showed that there was a significant association between hypertension and PU in COVID‐19 patients(OR = 1.73, 95% CI = 1.35–2.22, I 2 = 0%, p < 0.0001), 10 , 21 , 26 whereas no association was found in str...…”